Skip to content

US · ONCO · BIOTECHNOLOGY

Onconetix, Inc. (ONCO) intrinsic value and stock valuation

$2.89as of 2026-11-21 · Mkt cap 3.2M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Onconetix, Inc. DCF and intrinsic value

InvestorsCraft values ONCO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ONCO’s statements →

Onconetix, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cincinnati, OH 45202 onconetix.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$820K
20192025
Net income
-$-14.03M
20192025
Free cash flow
-$-9.68M
20192025
Total equity
$15.8M+27.2% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$820K$2.52M$60K$0.00$0.00
Operating income-$-6.34M-$-56.49M-$-36.03M-$-13.48M-$-3.42M
Net income-$-14.03M-$-58.69M-$-37.41M-$-13.42M-$-3.42M
EPSd-$-4.28M-$-533.55M-$-1.87B-$-1.34B-$-342M
Operating cash flow-$-9.68M-$-10.5M-$-13.58M-$-8.68M-$-2.04M
Capital expenditure$0.00-$-30K-$-60K-$-10K-$0.00
Free cash flow-$-9.68M-$-10.52M-$-13.64M-$-8.68M-$-2.05M
Total assets$24.9M$28.2M$87.5M$26.3M$3.08M
Total debt$50K$9.45M$9.89M$0.00$0.00
Net debt-$-5.17M$8.8M$5.33M-$-25.75M-$-1.93M
Total equity$15.8M$9.61M$1.4M$22.4M$1.45M
Cash and short-term investments$5.22M$650K$4.55M$25.8M$1.93M
Income statement
20252024202320222021
Revenue$820K$2.52M$60K$0.00$0.00
Cost of revenue$180K$1.47M$1.19M$10K$0.00
Gross profit$630K$1.06M-$-1.13M-$-10K-$0.00
Research and development expenses-$-70K$150K$1.95M$4.13M$1.33M
Selling, general and administrative expenses$7.04M$11.2M$14.8M$9.35M$2.09M
Other expenses$0.00$46.2M$18.2M$0.00$0.00
Operating expenses$6.98M$57.5M$34.9M$13.5M$3.42M
Cost and expenses$7.16M$59M$36.1M$13.5M$3.42M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$750K$1.41M$670K$0.00$0.00
Depreciation and amortization$20K$730K$40K$10K$0.00
Ebitda-$-13.27M-$-57.6M-$-36.71M-$-13.41M-$-3.41M
Operating income-$-6.34M-$-56.49M-$-36.03M-$-13.48M-$-3.42M
Total other income/expenses, net-$-7.69M-$-3.25M-$-1.39M$60K$0.00
Income before tax-$-14.03M-$-59.74M-$-37.42M-$-13.42M-$-3.42M
Income tax expense$0.00-$-1.05M-$-10K$0.00$0.00
Net income-$-14.03M-$-58.69M-$-37.41M-$-13.42M-$-3.42M
Weighted average shares outstanding$3.28M$110K$20K$10K$10K
Weighted average diluted shares outstanding$3.28M$110K$20K$10K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$5.22M$650K$4.55M$25.8M$1.93M
Net receivables$300K$100K$150K$40K$150K
Inventory$150K$60K$360K$0.00$0.00
Total current assets$6.07M$950K$5.84M$26.3M$3.07M
Property, plant and equipment, net$90K$180K$210K$10K$10K
Goodwill and intangible assets$18.6M$27.1M$81.1M$0.00$0.00
Long-term investments$0.00$250K$0.00$0.00$0.00
Total non-current assets$18.9M$27.2M$81.7M$50K$10K
Total assets$24.9M$28.2M$87.5M$26.3M$3.08M
Accounts payable$1.76M$3.79M$5.3M$1.5M$580K
Short-term debt$20K$9.45M$9.69M$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.14M$18.3M$17.2M$3.92M$1.64M
Long-term debt$20K$0.00$190K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$20K$280K$68.9M$0.00$0.00
Capital lease obligations$20K$120K$150K$0.00$0.00
Total liabilities$9.16M$18.6M$86.1M$3.92M$1.64M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-131.21M-$-115.68M-$-56.79M-$-19.38M-$-5.96M
Accumulated other comprehensive income (loss)-$-230K-$-2.72M$2.38M$0.00$0.00
Total equity$15.8M$9.61M$1.4M$22.4M$1.45M
Total investments$0.00$250K$0.00$0.00$0.00
Total debt$50K$9.45M$9.89M$0.00$0.00
Net debt-$-5.17M$8.8M$5.33M-$-25.75M-$-1.93M
Cash flow statement
20252024202320222021
Net income-$-14.03M-$-58.69M-$-37.41M-$-13.42M-$-3.42M
Depreciation and amortization$20K$730K$40K$10K$0.00
Stock-based compensation$70K$440K$330K$1.97M$130K
Change in working capital-$-2.42M-$-1.54M$1.62M$2.56M$1.21M
Accounts receivable-$-320K$120K-$-60K-$-20K-$-110K
Inventory-$-70K-$-60K-$-320K$0.00$0.00
Accounts payable-$-1.09M-$-1.48M$3.37M$1.09M$340K
Net cash provided by operating activities-$-9.68M-$-10.5M-$-13.58M-$-8.68M-$-2.04M
Investments in property, plant and equipment$0.00-$-30K-$-60K-$-10K-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-30K-$-8.65M-$-30K-$0.00
Common stock issued$20.2M$690K$0.00$34.9M$0.00
Common stock repurchased$0.00-$0.00-$-60K-$-570K$0.00
Dividends paid$0.00-$-210K$0.00$0.00$0.00
Net cash used for financing activities$14.5M$6.74M$1.04M$32.5M-$-330K
Net change in cash$4.57M-$-3.91M-$-21.2M$23.8M-$-2.38M
Cash at end of period$5.22M$650K$4.55M$25.8M$1.93M
Operating cash flow-$-9.68M-$-10.5M-$-13.58M-$-8.68M-$-2.04M
Capital expenditure$0.00-$-30K-$-60K-$-10K-$0.00
Free cash flow-$-9.68M-$-10.52M-$-13.64M-$-8.68M-$-2.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Onconetix, Inc.

        Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.

        CEO
        David Allan White
        Employees
        8
        Beta
        2.68

        Explore

        Frequently asked questions

        What is the intrinsic value of Onconetix, Inc. (ONCO)?

        Onconetix, Inc. (ONCO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ONCO undervalued?

        ONCO trades at a price of $2.89 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.